Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03810144 · ClinicalTrials.gov registry record
Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 444
- Enrollment target
NCT03810144: Completed study, sponsored by Sequenom.
NCT03810144 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 444 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03810144 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 444 participants
- Enrollment target
Study Summary
Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs.
Primary Outcome
Change in disease activity from baseline to month 9 as measured by mean MBDA score. MBDA Score stands for the Vectra multi-biomarker disease activity (MBDA) blood test. Scale: Low (\>30); Moderate (30-44); High (\>44)
Interventions
- GENETIC Vectra MBDA Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2022-10-16 |
What the finished NCT03810144 record still lists
NCT03810144 is an observational study that tracks outcomes without assigning an intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Vectra MBDA Test is the first listed.
NCT03810144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03810144 about?
NCT03810144 is a clinical study titled "Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test". Nine months multi-center prospective, randomized observational study, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs.
What is the current status of trial NCT03810144?
This trial is currently completed. The enrollment target is 444 participants. The study started on 2018-10-22. Estimated completion is 2022-10-16.
What interventions are being tested in trial NCT03810144?
The interventions under investigation include: Vectra MBDA Test (GENETIC).
Who is sponsoring clinical trial NCT03810144?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI